1. Home
  2. INSM

INSM

Insmed Incorporated

Logo Insmed Incorporated

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-15-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Founded: 1988 Country:
United States
United States
Employees: N/A City: BRIDGEWATER
Market Cap: 4.0B IPO Year: 2000
Target Price: $45.36 AVG Volume (30 days): 1.6M
Analyst Decision: Strong Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.34 EPS Growth: N/A
52 Week Low/High: $16.46 - $32.00 Next Earning Date: 05-02-2024
Revenue: $305,208,000 Revenue Growth: 24.39%
Revenue Growth (this year): 18.97% Revenue Growth (next year): 45.07%

Share on Social Networks: